Summary
Global Markets Direct’s, ‘AiCuris GmbH & Co. KG - Product Pipeline Review - 2016’, provides an overview of the AiCuris GmbH & Co. KG’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by AiCuris GmbH & Co. KG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of AiCuris GmbH & Co. KG
- The report provides overview of AiCuris GmbH & Co. KG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses AiCuris GmbH & Co. KG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features AiCuris GmbH & Co. KG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate AiCuris GmbH & Co. KG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for AiCuris GmbH & Co. KG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding AiCuris GmbH & Co. KG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
AiCuris GmbH & Co. KG Snapshot 5
AiCuris GmbH & Co. KG Overview 5
Key Information 5
Key Facts 5
AiCuris GmbH & Co. KG - Research and Development Overview 6
Key Therapeutic Areas 6
AiCuris GmbH & Co. KG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
AiCuris GmbH & Co. KG - Pipeline Products Glance 13
AiCuris GmbH & Co. KG - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
AiCuris GmbH & Co. KG - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
AiCuris GmbH & Co. KG - Drug Profiles 17
pritelivir 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AIC-284 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AIC-649 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
AIC-277 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
AIC-499 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Drug for Infectious Disease 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule 1 for Gram-Negative Bacterial Infections 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule 2 for Gram-Negative Bacterial Infections 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecule for Gram-Positive Bacterial Infections 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule for Infectious Disease 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Viral Infections 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AiCuris GmbH & Co. KG - Pipeline Analysis 29
AiCuris GmbH & Co. KG - Pipeline Products by Target 29
AiCuris GmbH & Co. KG - Pipeline Products by Route of Administration 30
AiCuris GmbH & Co. KG - Pipeline Products by Molecule Type 31
AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action 32
AiCuris GmbH & Co. KG - Recent Pipeline Updates 33
AiCuris GmbH & Co. KG - Dormant Projects 35
AiCuris GmbH & Co. KG - Locations And Subsidiaries 36
Head Office 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38
List of Tables
AiCuris GmbH & Co. KG, Key Information 5
AiCuris GmbH & Co. KG, Key Facts 5
AiCuris GmbH & Co. KG - Pipeline by Indication, 2016 8
AiCuris GmbH & Co. KG - Pipeline by Stage of Development, 2016 9
AiCuris GmbH & Co. KG - Monotherapy Products in Pipeline, 2016 10
AiCuris GmbH & Co. KG - Out-Licensed Products in Pipeline, 2016 11
AiCuris GmbH & Co. KG - Out-Licensed Products/ Combination Treatment Modalities, 2016 12
AiCuris GmbH & Co. KG - Phase II, 2016 13
AiCuris GmbH & Co. KG - Phase I, 2016 14
AiCuris GmbH & Co. KG - Preclinical, 2016 15
AiCuris GmbH & Co. KG - Discovery, 2016 16
AiCuris GmbH & Co. KG - Pipeline by Target, 2016 29
AiCuris GmbH & Co. KG - Pipeline by Route of Administration, 2016 30
AiCuris GmbH & Co. KG - Pipeline by Molecule Type, 2016 31
AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action, 2016 32
AiCuris GmbH & Co. KG - Recent Pipeline Updates, 2016 33
AiCuris GmbH & Co. KG - Dormant Developmental Projects,2016 35
List of Figures
AiCuris GmbH & Co. KG - Pipeline by Top 10 Indication, 2016 7
AiCuris GmbH & Co. KG - Pipeline by Stage of Development, 2016 9
AiCuris GmbH & Co. KG - Monotherapy Products in Pipeline, 2016 10
AiCuris GmbH & Co. KG - Out-Licensed Products in Pipeline, 2016 11
AiCuris GmbH & Co. KG - Pipeline by Target, 2016 29
AiCuris GmbH & Co. KG - Pipeline by Route of Administration, 2016 30
AiCuris GmbH & Co. KG - Pipeline by Top 10 Molecule Type, 2016 31
AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action, 2016 32
